<DOC>
	<DOC>NCT02326272</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Provided informed consent Adult men or women ≥ 18 years Chronic plaque psoriasis for at least 6 months Baseline psoriasis activity and severity index ≥ 12 and body surface area ≥ 10 % and Physician's Global Assessments score ≥ 3 Candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy Other protocoldefined inclusion criteria may apply Erythrodermic, guttate, generalized pustular form of psoriasis History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol Congestive heart failure History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease History of other malignancy concurrent malignancy as described in the protocol History of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis) Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 3 months following last dose of study drug. Male subjects who are planning a partner pregnancy during the study or within 10 weeks following the last dose Any other condition which, in the Investigator's judgment, would make the subject unsuitable for participation in the study Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Psoriasis</keyword>
</DOC>